How TAVI registries report clinical outcomes—A systematic review of endpoints based on VARC-2 definitions

Shixuan Zhang¹*, Peter L. Kolominsky-Rabas¹,²

¹ Interdisciplinary Centre for Health Technology Assessment (HTA) and Public Health (IZPH), Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Bavaria, Germany, ² National Leading-Edge Cluster Medical Technologies “Medical Valley EMN”, Erlangen, Bavaria, Germany

* Shixuan.Zhang@uk-erlangen.de

Abstract

Introduction
Transcatheter aortic valve implantation (TAVI) has been demonstrated to be an alternative treatment for severe aortic stenosis in patients considered as high surgical risk. Since its first human implantation by Cribier et al., TAVI has been shown to increase survival rate and quality of life for high surgical risk patients. The objective of this study is to provide an overview of TAVI registries and the reporting clinical outcomes based on the VARC-2 definitions. In addition, the comparability and adherence of VARC-2 reporting within the identified TAVI registries was reviewed.

Materials and methods
A systematic review of TAVI registries reporting VARC-2 definitions has been performed in line with PRISMA guidelines in PubMed, ScienceDirect, Scopus databases and EMBASE. Based on VARC-2, patients' characteristics and procedure characteristics, 30-day clinical outcomes, 1-year mortality and composited endpoints were extracted from each registry's publications.

Results
This review identified 466 studies that were potentially relevant, and 20 TAVI registries reported VARC-2 definitions involved in our present review. Of all 20 registries, an overall sample size of 12,583 patients was involved. The 30-day all-cause mortality ranged from 0 to 12.7%. From 20 registries, 14 registries reported the cardiovascular mortality at 30 days. 9 registries reported myocardial infarction (MI) rate based on VARC-2 definitions, and 7 registries reported peri-procedural MI rate (<72h). In our review, most of registries presented MI rates ranging from 0.5% to 2%. The majority of registries have reported complications such as bleeding, vascular complications and new pacemaker implantation.

Conclusion
Since the introduction of VARC definitions from 2011, VARC and VARC-2 definitions are still not systematically used by all TAVI studies. These endpoint definitions warrant a
1. Introduction

1.1 Rational

The aortic stenosis (AS) is the most common valvar heart disease in developed countries [1], which affects 2% of the population aged 65 years or older [2]. Open surgical aortic valve replacement (SAVR) is the standard care in the treatment of symptomatic AS patients [3]. However, about 30% to 50% of patients with severe AS do not undergo surgery for a variety of high surgical risks such as age and comorbidities [4]. Transcatheter aortic valve implantation (TAVI) has been demonstrated to be an alternative treatment for severe AS in patients considered as high risk for SAVR [5,6].

Since its first human implantation by Cribier et al. [7], TAVI has been shown to increase survival rate and quality of life for high surgical risks patients [8,9]. However, the fast growth of TAVI has created difficulties in cross-study result comparison. Since the investigators were not prepared to interpret clinical data in a standardized way, it made clinical data reporting difficult [10]. In October 2011, the first European consensus document on TAVI, called Valve Academic Research Consortium (VARC), with standardized definitions on clinical endpoints, was published [10]. The goals of VARC are combining the expertise to arrive at a consensus for selecting appropriate clinical endpoints and standardizing definitions for single and composite clinical endpoints [10]. Two years later, it has been subsequently revised in the VARC-2 definitions [11]. The VARC-2 definition is an updated version from the VARC definition. It clearly indicated that all-cause mortality, cardiovascular and non-cardiovascular mortality should be reported after 30 days. In addition, for the major complications, the VARC-2 revisited the selection and definitions of TAVI-related clinical endpoints to make them more suitable to the present and future’s needs of clinical trials. The VARC-2 definitions also aim expanding the understanding of patient risk stratification and case selection, indicate using Logistic EuroScore and Society of Thoracic Surgeons Predicted Risk of Mortality score (STS-Score) to select suitable patients.

1.2 Objectives

The aim of this study is to provide an overview of TAVI registries and their reporting clinical outcomes based on the VARC-2 definitions. In addition, the comparability and adherence of VARC-2 reporting within the identified TAVI registries was reviewed.

2. Methods

2.1 Search methodology

The review was employed in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines [12]. The PubMed (Medline), the ScienceDirect, the Scopus database and the EMBASE were searched to identify all reports describing TAVI registries adapted to the VARC-2 definitions. The following search terms were used: “registry”, concise and systemic analysis of outcome measures. Reporting TAVI-outcome uniformly makes study result comparison feasible. This definitely will increase patient safety, additionally to provide sufficient evidence to support decision makers like regulatory bodies, HTA agencies, payers.
“Valve Academic Research Consortium” and “VARC”. Studies were also identified by scanning articles’ reference lists through citation snowballing, as well as gray literature searching.

2.2 Study selection
The articles describing TAVI registries adapting to the VARC-2 definitions were included in this review, additionally the TAVI registries were only for patients with aortic stenosis. Inclusion criteria and exclusion criteria for this review were listed in Table 1. No publication time restriction was used. The searching language was limited to English. The potential relevant title and abstract has been reviewed by two independent researchers after removing the duplicated studies. When studies presented duplicated patient cohorts, the most complete or updated reports will be selected.

2.3 Data extraction and quality of study assessment
Based on the VARC-2 clinical endpoint definitions, the following information was extracted from each registry’s publications [10,11]: patients’ characteristics and procedure characteristics including number of patients, type of device, access route, inclusion period, the Society of Thoracic Surgeons score (STS) (%), the Logistic EuroScore (%) and mean follow-up; 30-day clinical outcomes including: all-cause mortality, cardiovascular mortality (CV mortality), myocardial infarction (MI), stroke, bleeding, acute kidney injury (AKI), vascular complications and need for new permanent pacemaker (PPM); 1-year mortality; compositive endpoints including: device success (72h), clinical efficacy (30 day), early safety (30 day) and time-related valve safety. The detailed description of each major complication can be found in Kappetein et al. of guideline on using of VARC-2 definitions [11], which will be also briefly described in the result parts. Two researchers independently extracted data and rated the risk bias. The quality of observational studies included in our review was appraised by Newcastle-Ottawa Scale (selection, comparability, and outcome) criteria [13]. We assessed the possibility of publication bias both visually and formally to check if the publication contains description of each major complication based on VARC-2. For each subgroup of major complication, the authors list the major findings in the result part and analyze them in discussion part, respectively.

3. Results

3.1 Bibliographic research results
This study identified 466 studies that were potentially relevant. Of all these studies, 37 originated from the PubMed (Medline) database, 274 from the Scopus database, 114 from the ScienceDirect and 41 were from the EMBASE. After removing duplicates, 323 abstracts have
been reviewed independently by two researchers. According to the inclusion criteria and exclusion criteria, 197 studies from 74 registries were put into full text review. After full text reviewing, 69 studies from 20 registries were involved in the analysis in this study (Fig 1).

### 3.2 Study characteristics

20 TAVI registries reported VARC-2 definitions involved in our present review, the first publication of VARC-2 for TAVI registry study was published in 2013 [14]. The earliest inclusion time period was from 2005 to 2011 in the PRAGMATIC Multicenter Study [15]. Of all 20 registries, an overall sample size of 12,583 patients was involved in the present review. 6 registries with 4,607 patients (36.61%) used “Balloon-expandable SAPIEN Prosthesis” of Edwards Lifesciences (Irvine, California)[16–21], and one registry with 1,316 patients (10.46%) used “Self-expandable CoreValve Prosthesis” from Medtronic CoreValve (Minneapolis, Minnesota)[22], 10 registries with total 6,406 patients used both prostheses of SAPIEN Edwards and Medtronic CoreValve [23–31]. In addition, one registry with 154 patients used Lotus Valve System (Boston Scientific, MA) [32]; and one registry with 100 patients used a nonmetallic design TAVI system—Direct Flow Medical (DFM) TAVI system [33]. Transfemoral (TF) and transapical (TA) are two commonly used access routes in TAVI [34]. About 79.5% patients underwent TF access route, and the other 20.5% patients underwent non-TF route including TA, transaortic (TAo), subclavian (SC), transcarotid (TC), transaxillary (TAX) and direct aortic access route.

The results of our review are presented according to patients’ characteristics and procedure characteristics, mortality, each major complication category based on VARC-2 definitions in the following text. The pre-operative characteristics of patients from each registry are showed in Table 2, and the endpoints based on VARC-2 definitions for each registry are showed in Table 3.
Table 2. Study characteristics with patient characteristics and procedure characteristics.

| Study                                      | Type of device                      | Number of patients | Access Route | Inclusion period | STS (%) | Logistic EuroScore (%) | Mean Follow-up |
|--------------------------------------------|-------------------------------------|--------------------|--------------|------------------|---------|------------------------|----------------|
| Balloon-expandable Sapien Prosthesis Registry | The ITER Registry [20]             | SAPIEN XT 1303 (68.4), Edwards SAPIEN 601 (31.6) | 1904         | TF 1252 (65.8), TA 630 (33.1), T Ao 18 (1), T A x 4 (0.2) | 11.2007–12.2012 | 9.2 ±7.6 | 21.1±13.7 | 773 days* |
|                                            | The PARTNER II SAPIEN 3 Registry [18] | SAPIEN 3 THV       | 583 (HR/inoperable group) | TF 491 (84.2), TA 57 (9.8), T Ao 35 (6.0) | 10.2013–02.2014 | 8.7 ±3.7 | -          | -       |
|                                            |                                    | SAPIEN 3 THV       | 1078 (Intermediate risk group) | TF 952 (88.3), TA 81 (7.5), T Ao 45 (4.2) | 02.2014–12.2014 | 5.3 ±1.3 | -          | -       |
|                                            | A Spanish single center TAVI Registry [19] | SAPIEN XT, SAPIEN  | 79           | TF 64 (81), TA 15 (19) | 06.2008–06.2012 | 5.9 ±2.9 | 16.9±9.1 | 28 m     |
|                                            | The Swiss TAVI Registry [17]       | Sapien 3           | 153          | TF 133 (86.0) | 02.-06.2014   | 7.1 ±6.5 | 23.7±15.9 | 30 days  |
|                                            |                                    | Sapien XT          | 445          | TF 390 (87.6) | 02.2011–01.2014 | 8.5 ±7.9 | 21.0±15.9 | 30 days  |
|                                            | Rouen TAVI Registry [16]           | SAPIEN XT 161 (68.2), Edwards SAPIEN | 236         | TF               | 05.2006–09.2012 | -          | 20.6 ±11.5 | 369 days |
|                                            | The SOURCE ANZ Registry [21]       | SAPIEN              | 129          | TF 67; TA 62   | 12.2008–12.2010 | - (26.8–28.8)* | 1 year |
| Self-expandable CoreValve Prosthesis Registry | The Italian CoreValve Registry [22] | CoreValve          | 1316         | TF 1073 (81.6), SC 192 (14.6), T Ao 50 (3.8) | 06.2007–12.2012 | - | 20 (13–30) | 13 m     |
|                                            | Mixed Registry                     | Mixed TAVI         | 1019         | TF 923 (90.6), SC 26 (2.6), TA 26 (2.6), T Ao 44 (4.3) | 01.2013–12.2015 | 8.3 ±7.4 | 17.8±11.7 | -       |
|                                            | The Pooled-Rotterdam-Milano-Toulouse Registry [30] | Mixed TAVI         | 166          | -               | 02.2014–05.2014 | 6.4 (4.0–11.5) | 16.7 (11.2–26.6) | -       |
|                                            | The Asian TAVR Registry [31]       | Edwards SAPIEN; Medtronic CoreValve | 848         | TF 731, Non-TF 117 | 03.2010–09.2014 | 5.2 ±3.8 | 16.5±12.0 | -       |
|                                            | The Japanese OCEAN TAVI Registry [25] | OCEAN-TAVI: Edwards SAPIEN XT | 134         | TF               | 10.2013–09.2014 | - | 18.8±13.3 | 1 year |
|                                            | Nassy database [25]                | Nassy database: Edwards SAPIEN XT; Edwards SAPIEN 3; Medtronic CoreValve | 178         | TF               | 10.2013–09.2014 | - | 16.1±13.1 | 1 year |
|                                            | TAVI-Karlsruhe Registry [28]       | Edwards SAPIEN/ SAPIEN XT THV n = 402; Symetis Acurate n = 11 | 1000        | TA 413           | 05.2008–04.2012 | - | 24.3±16.2 | 1371 days |
|                                            |                                    | Edwards SAPIEN/ SAPIEN XT n = 399; Medtronic CoreValve n = 188 |   | TF 587 | - | 22.2±16.2 |   |
|                                            | The Brazilian Registry [24]        | CoreValve; Sapien XT | 418         | TF 402 (96.2), T Ao 6 (1.2), T C 1 (0.2), SC 9 (2.2) | 01.2008–01.2013 | 14±11 | 20.2±13.8 | 343.5 days |
|                                            | The PRAGMATIC Multicenter Study [15] | SAPIEN XT, SAPIEN, CoreValve | 1062        | -               | 11.2005–12.2011 | 8.7 ±6.5 | 22.5±13.3 | 2 years |

(Continued)
3.2.1 Pre-operative characteristics. Logistic EuroSCORE (LES) and Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) score are commonly used in clinical trials to identify high-risk surgical or “inoperable” patients for TAVI [35]. The logistic Euroscore calculated by means of a logistic regression equation, ranges from 0 to 100%, with high scores indicating greater risks and a score of more than 20% indicating high surgical risks [36]. In addition, the STS score >8 is defined as “high risk”, 4–8 is defined as “Moderate risk” [11]. 12 registries in our review presented the STS score, the mean STS score ranged from 5.2% in the Asian TAVR Registry to 14% in the Brazilian Registry [24,31]. 18 out of 20 registries in our review reported the logistic EuroScore, the mean Logistic EuroScore ranged from 16.1% in Nassy Database to 33.1% in the Royal Prince Alfred Hospital TAVI Program [25,26]. The shortest mean follow-up period was in the Swiss TAVI Registry, which was 30 days [17]. The longest mean follow-up period was in the TAVI-Karlsruhe Registry, which was 1,371 days [28]. All other registries have a mean follow-up over 1 year.

3.2.2 Mortality. According to the VARC-2 definitions, “all-cause, cardiovascular, and non-cardiovascular mortality should be reported after 30 days during the follow-up [11].” The 30-day all-cause mortality ranged from 0 in OCEAN-TAVI Registry to 12.7% in a Spanish single center TAVI Registry [19,25]. In the present review, from 20 registries, 14 registries reported the CV mortality at 30 days. The ratio of CV mortality in all-cause mortality at 30 days ranged from 50% in a Spanish single center TAVI Registry to 96.8% in the University Hospital Zurich TAVI Registry [19,29]. 18 out of 20 registries in our review reported the logistic EuroScore, the mean Logistic EuroScore ranged from 16.1% in Nassy Database to 33.1% in the Royal Prince Alfred Hospital TAVI Program [25,26]. The shortest mean follow-up period was in the Swiss TAVI Registry, which was 30 days [17]. The longest mean follow-up period was in the TAVI-Karlsruhe Registry, which was 1,371 days [28]. All other registries have a mean follow-up over 1 year.

3.2.3 Myocardial infarction. VARC-2 recommends the systematic collection of biomarkers of myocardial injury prior to the procedure, within 12–24 hours after the procedure, at 24 hours thereafter, at 72 hours or at discharge [11]. The definition of periprocedural MI will be based on a combination of clinical criteria and cardiac biomarkers within 72 hours following

---

Table 2. (Continued)

| Study                                         | Type of device                  | Number of patients | Access Route | Inclusion period       | STS (%) | Logistic EuroScore (%) | Mean Follow-up |
|-----------------------------------------------|---------------------------------|--------------------|--------------|------------------------|---------|------------------------|----------------|
| Multicenter registry from North America, South America and Europe [27] | SAPIEN, SAPIEN XT, SAPIEN 3, CoreValve | 1131               | TF 73.1%, TA 20.3%, Tao 4.3%, SC 2.3% | 03.2007–12.2014 | 8.2 ± 6.8 | -                      | 21 m           |
| The Royal Prince Alfred Hospital TAVI Program [26] | Edwards SAPIEN; Medtronic CoreValve | 100                | TF 68; TA 32 | 06.2009–07.2013        | -       | 33.1 ± 22.6            | 17 m           |
| The University Hospital Zurich TAVI Registry [29] | Edwards SAPIEN 158 (45), Medtronic CoreValve 189 (54), Engager 3 (1) | 350                | TF 289 (83%) | 05.2008–11.2012        | -       | 22.1 ± 13.8            | 389 days       |
| Nordic Lotus-TAVR registry [32]               | Lotus Valve System             | 154                | TF 151 (98.1), Direct aortic 3 (1.9) | -         | 5.0 ± 2.8              | -              |
| DISCOVER Study [33]                           | Direct Flow Medical (DFM)      | 100                | -            | -                      | 9.7 ± 8.7 | 22.5 ± 11.3            | 1 year         |

*median follow-up
(26.8–28.8) *: the original data was taken from two groups
Tax = Transaxillary; Tao = Transaortic; SC = Subclavian; TC = Transcarotid

https://doi.org/10.1371/journal.pone.0180815.t002
Table 3. Results of individual study based on VARC-2 Recommendations.

| Study | All-cause mortality (30 days) | Cardiovascular mortality (30 days) | Mortality (1 year) | Myocardial infarction, n (%) | Stroke, n (%) | Bleeding, n (%) | Acute kidney injury, n (%) | Vascular access site and access-related complications, n (%) | Need for new PPM, n (%) |
|-------|-----------------------------|----------------------------------|-------------------|-----------------------------|---------------|-----------------|--------------------------|-------------------------------------------------------------|----------------------|
|       |                             |                                  |                   |                             |               |                 |                          |                                                             |                      |
| Balloon-expandable Sapien Prosthesis Registry |                             |                                  |                   |                             |               |                 |                          |                                                             |                      |
| The ITER Registry [20] | 137 (7.2) | - | 286 (15.0) | 29 (1.5)* | 54 (2.8) | 499 (26.2) | 155 (8.6)* | 314 (16.5) | 116 (6.1) |
| The PARTNER II SAPIEN 3 Registry [18] | - HR/inoperable | 13 (2.2) | 8 (1.4) | - | 3 (0.5) | 12 (2.1) | 117 (24.2)* | 50 (7.6) | 75 (12.9) | 77 (13.3) |
| - IR | 12 (1.1) | 10 (0.9) | - | 3 (0.3) | 34 (3.2) | 164 (15.2)* | 56 (5.2) | 131 (12.2) | 109 (10.1) |
| A Spanish single center TAVI Registry [19] | (12.7) | (6.35) | (25.4) | 2 (2.6) | 2 (2.6) | 9 (11.4) | 14 (17.8) | 12 (15.2) | 3 (3.8) |
| The Swiss TAVI Registry [17] | -Sapien 3 | 5 (3.3) | 4 (2.6) | - | 2 (1.3) | 2 (1.3) | 14 (9.2) | 7 (4.6) | 8 (5.2) | 26 (17.0) |
| -Sapien XT | 20 (4.5) | 19 (4.3) | - | 0 (0.0) | 18 (4.0) | 66 (14.8) | 26 (5.8) | 75 (16.9) | 48 (11.0) |
| Rouen TAVI Registry [16] | 11 (4.7) | - | (23.2) | - | - | 18 (7.8)* | 55 (23.3) | -33 (14.0) | - |
| The SOURCE ANZ Registry [21] | 10 (7.8) | - | 23 (17.8) | 5 (3.9) | 5 (3.9) | - | 20 (15.6) | 13 (10.1) | 6 (4.7) |
| Self-expandable CoreValve Prosthesis Registry |                             |                                  |                   |                             |               |                 |                          |                                                             |                      |
| The Italian CoreValve Registry [22] | 80 (6.1) | 62 (4.7) | - | 13 (0.9) | 27 (2.0) | 348 (26.4) | 234 (17.8)* | 93 (7.1)* | 311 (23.6) |
| Mixed Registry |                             |                                  |                   |                             |               |                 |                          |                                                             |                      |
| WIN-TAVI Real-World Registry [23] | 40 (3.4) | 38 (3.3) | - | 2 (0.2) | 13 (1.3) | 45 (4.4)* | 13 (1.3)* | 80 (7.7)* | 118 (11.6) |
| The Pooled-Rotterdam-Milano-Toulouse Registry [30] | 10 (6.0) | 8 (4.8) | - | - | - | 6 (3.6) | 4 (2.4)* | 12 (7.2) | 8 (4.8)* | 27 (16.2) |
| The Asian TAVR Registry [31] | 21 (2.5) | 14 (1.7) | 81 (10.8) | - | 32 (3.8) | 92 (10.8) | 28 (3.3)* | 82 (9.7) | 80 (9.5) |
| Inohara et al. 2016 (26) |                             |                                  |                   |                             |               |                 |                          |                                                             |                      |
| The Japan OCEAN TAVI Registry | 0 (0) | 0 (0) | - | 2 (1.5)* | 2 (1.5) | 23 (17.2) | 2 (1.5)* | 17 (12.7) | 8 (6.0) |
| Nassy database | 1 (0.6) | 1 (0.6) | - | 0 (0)* | 1 (0.6) | 30 (16.8) | 2 (1.1)* | 27 (15.2) | 39 (21.9) |
| TAVI-Karlsruhe Registry [28] |                             |                                  |                   |                             |               |                 |                          |                                                             |                      |
| -TA | (6.1) | (4.1) | - | (2.7)* | (1.7) | (28.8) | (35.1) | (2.9) | (10.7) |
| -TF | (6.5) | (5.1) | - | (1.7)* | (2.3) | (28.6) | (19.9) | (19) | (15.7) |
| The Brazilian Registry [24] | (9.1) | (7.9) | (21.5) | 0.7 | (3.5) | (18.5) | (20.0) | (13.8) | (24.4) |
| PRAGMATIC Multicenter Study [16] | 63 (5.9) | 56 (5.3) | 187 (18.5) | 12 (1.1)* | 42 (4) | 460 (43.3) | 257 (24.2) | 227 (21.4) | 165 (15.6) |

(Continued)
### Table 3. (Continued)

| Study | All-cause mortality (30 days) | Cardiovascular mortality (30 days) | Mortality (1 year) | Myocardial infarction, n (%) | Stroke, n (%) | Bleeding, n (%) | Acute kidney injury, n (%) | Vascular access site and access-related complications, n (%) | Need for new PPM, n (%) |
|-------|-------------------------------|------------------------------------|-------------------|-----------------------------|--------------|----------------|--------------------------|---------------------------------------------------------------|------------------------|
| Multicenter registry from America and Europe [27] | 65 (5.7) | - | - | - | 40 (3.5) | 57 (5.0)* | - | 136 (12.0)* | 173 (15.3) |
| The Royal Prince Alfred Hospital TAVI Program [26] | 3 (3.0) | 2 (2.0) | 7 (7.0) | 2 (2.0)* | 4 (4.0) | 30 (30.0) | 16 (16.0) | 17 (17.0) | 13 (13.0) |
| The University Hospital Zurich TAVI Registry [29] | 32 (9.1) | 31 (8.7) | (21.0) | (2.0) | (2.9) | (4.6) | (5.7) | (7.4) | (18.9) |
| Nordic Lotus-TAVR registry [32] | 3 (1.9) | - | - | - | 5 (3.2) | 3 (1.9)* | 2 (1.3)* | 4 (2.6)* | 43 (27.9%) |
| DISCOVER Study [33] | 1 (1.0) | 1 (1.0) | 10 (10.0) | 1 (1.0) | 7 (7.0) | 9 (9.0)* | 1 (1.0)* | 13 (13.0) | 17 (17.0) |

29 (1.5)*, 2 (1.5)*, 0 (0)*, (2.7)*, (1.7)*, 12 (1.1)* and 2 (2.0)* in Myocardial infarction list are for Periprocedural MI (<72h) In the bleeding list, 117 (24.2)*, 164 (15.2)* and 57 (5.0)* are for Life-threatening/disabling and Major bleeding; 18 (7.6)*, 45 (4.4)*, 4 (2.4)* and 3 (1.9)* are for Life-threatening bleeding; 9 (9.0)* is for Major bleeding In the AKI list, 155 (8.6)*, 13 (1.3)*, 28 (3.3)* and 2 (1.3)* are for Acute kidney injury, stage 2 or 3; 234 (17.8)*, 2 (1.5)*, 2 (1.1)* and 1 (1.0)* are for Acute kidney injury Stage 3 In vascular complications list, 93 (7.1)*, 80 (7.7)*, 8 (4.8)*, 136 (12.0)* and 4 (2.6)* are for Major vascular complications

https://doi.org/10.1371/journal.pone.0180815.t003

TAVI [11]. 9 registries reported MI rate based on VARC-2 definitions, and 7 registries reported peri-procedural MI rate (<72h). In our review, most of registries presented MI rates ranging from 0.5% to 2%. The SOURCE ANZ Registry reported a higher MI rate of 3.9%. The TA-TAVI group with 62 patients in this registry achieved an even higher MI rate, was 6.45% [21]. The similar results could be found in the TAVI-Karlsruhe Registry, where peri-procedural MI occurred in 2.7% of 413 patients underwent TA route [28].

#### 3.2.4 Stroke.
VARC-2 recognizes that an assessment of stroke is incomplete without an appropriate measurement of the disability resulting from the stroke. VARC-2 now recommends the use of terms “disabling” and “nondisabling” [11]. In the present review, 19 registries report all including disabling stroke, non-disabling stroke and TIA based on VARC-2 definitions. It ranged from 0.6% in Nassy Database to 7% in a single registry [25,33].

#### 3.2.5 Bleeding.
VARC definition of bleeding complications is divided into life-threatening or disabling bleeding, major bleeding, and minor bleeding [10,11]. For the present review, 14 registries reported all bleeding complications, 18 registries reported life-threatening bleeding at 30 days after TAVI, and 17 registries reported major bleeding. The overall bleeding rate ranged from 4.6% in the University Hospital Zurich TAVI Registry [29] to 43.3% in the PRAGMATIC Multicenter Study [15].

#### 3.2.6 Acute kidney injury (AKI).
VARC-2 recommends diagnosing AKI at 30 days based on increasing in serum creatinine and urine output, which can be categorized into stages 1 to 3. Stage 3 indicates the most serious level. 19 registries reported AKI complications, most of them having rates of AKI with 2.0% to 3.0%. However, in the ITER Registry and the PRAGMATIC Multicenter Study, AKI stage 2 to stage 3 at 30 days occurred in 8.14% and 9.23% patients, respectively [15,22].
3.2.7 Vascular complications. VARC-2 lists major and minor vascular complications. 19 registries reported the major vascular complications, ranged from 2.42% in the TA group of the TAVI-Karlsruhe Registry [28], to 17.54% of patients undergoing TF route in the TAVI-Karlsruhe Registry [28].

3.2.8 New pacemaker implantation. VARC-2 proposes the systematic collection of data on the frequency of implant-related new permanent pacemaker implantation [11]. 18 registries reported the patient number in which implanted a new pacemaker. The rate from pure Edwards registries ranged from 3.8% to 17.0% [17,19]. In the pure CoreValve registry, 23.63% of patients needed a new pacemaker after TAVI [22]. In addition, both of the new Lotus Valve System and Direct Flow Medical (DFM) system had a higher requirement of pacemaker, with a rate of 27.9% and 17.0%, respectively.

3.2.9 Composite endpoints. The composite endpoints according to VARC-2 definition included: (1) device success, (2) early safety at 30 days, (3) clinical efficacy after 30 days and (4) time-related valve safety. Device success indicates the absence of procedural mortality, correct positioning of a single prosthetic heart valve as well as intended performance of the prosthetic heart valve. Early safety is a combined endpoint at 30 days including all-cause mortality, all stroke, life-threatening bleeding (LT bleeding), AKI-stage 2 or 3, coronary artery obstruction.

Table 4. Composite endpoints from individual studies based on the VARC-2.

| Study                                      | Device success | Clinical efficacy (30 day) | Early safety (30 day) |
|--------------------------------------------|----------------|----------------------------|-----------------------|
| **Balloon-expandable Sapien Prosthesis Registry** |                |                            |                       |
| The ITER Registry [20]                    | 88.1           | 1030 (54.1)                | 1418 (74.5)           |
| The PARTNER II SAPIEN 3 Registry [18]     | -              | -                          | -                     |
| A Spanish single center TAVI Registry [19] | 69 (87.3)      | 52 (65.8)                  | 55 (69.6)             |
| The Swiss TAVI Registry [17]              | -              | -                          | -                     |
| -Sapien 3                                 | -              | -                          | -                     |
| -Sapien XT                                | -              | -                          | -                     |
| Rouen TAVI Registry [16]                  | 219 (92.8)*    | -                          | -                     |
| The SOURCE ANZ Registry [21]              | -              | -                          | -                     |
| **Self-expandable CoreValve Prosthesis Registry** |                |                            |                       |
| The Italian CoreValve Registry (22)       | 1,241 (94.7%)  | -                          | -                     |
| **Mixed Registry**                        |                |                            |                       |
| WIN-TAVI Real-World Registry [23]         | -              | -                          | 147 (14.0)            |
| The Pooled-Rotterdam-Milano-Toulouse Registry [30] | -              | -                          | -                     |
| The Asian TAVR Registry [31]              | 725 (85.5)     | -                          | 124 (14.6)            |
| Inohara et al. 2016 (26)                  |                |                            |                       |
| The Japan OCEAN TAVI Registry             | 131 (97.8)     | -                          | 13 (9.7)              |
| Nassy database                            | 174 (97.8)     | -                          | 20 (11.2)             |
| TAVI-Karlsruhe Registry [28]              | -              | -                          | -                     |
| The Brazilian Registry [24]               | 319 (76.3)     | -                          | 22.7                  |
| PRAGMATIC Multicenter Study [15]          | 974 (91.7)     | -                          | 308 (29)              |
| Multicenter registry from America and Europe [27] | 879 (78.8)     | -                          | -                     |
| The Royal Prince Alfred Hospital TAVI Program [26] | 94.0           | -                          | 86 (86)               |
| The University Hospital Zurich TAVI Registry [29] | 88.0           | -                          | 67 (19.1)             |
| **Other TAVI Registry**                   |                |                            |                       |
| Nordic Lotus-TAVR registry [32]           | -              | 141 (91.6)                 | 142 (92.2)            |
| DISCOVER Study [33]                      | 91.0           | -                          | 10.0                  |
*device failure rate in this study is 7.2%.

https://doi.org/10.1371/journal.pone.0180815.t004
requiring intervention, major vascular complication and valve-related dysfunction requiring repeat procedure. Clinical efficacy is a combined endpoint after 30 days including all-cause mortality, all-stroke, requiring hospitalizations for valve-related symptoms or worsening congestive heart failure, NYHA class III or IV as well as valve-related dysfunction. Time-related valve safety combines valve dysfunction, endocarditis, and thrombotic complications of the prosthesis. In our review, 13 studies reported device success rate, which ranged from 76.3% to 97.8% [15,16,19,20,22,25–27,29,31,33,37]. 11 studies reported early safety rate, but it ranged from 10% to 92.2% [15,19,20,23–26,29,31–33]. Only three registries reported clinical efficacy [19,20,32]. There is no registry reported time-related valve safety. Detail information for each registry was described in Table 4.

4. Discussion
To our knowledge, this is the first systematic review analyzing clinical outcome reporting based on VARC-2 definitions. TAVI has become the fastest growing cardiac procedure since the introduction of coronary stents, with penetration rates of over 35% in countries such as Switzerland and Germany [38], where this rate has achieved to 52% in 2015 [39]. Despite this growth, there was a lack of standardized reporting on clinical outcomes for patients undergoing TAVI before the introduction of VARC and VARC-2 definitions. As demonstrated and confirmed by Genereux et al. in a pooled analysis of 3,519 patients, VARC definitions already represent a new standard for consistency in reporting clinical outcomes for patients undergoing TAVI [40]. The VARC-2 is an updated version of the original VARC. In the results section above, the authors summarized the registries reports using VARC-2 definitions based upon mortality as well as major complication categories. To address and support patients’ safety and procedural quality as demanded by regulatory bodies and HTA agencies, three main parts are needed to be taken into discussion: first of all, the authors provide the summary of the proportion use VARC-2 overall all TAVI registries; and investigate the trends of research in the field of TAVI since the introduction of VARC definitions; Secondly, the authors highlight important notices of reporting status for each complication, meanwhile, the authors compare the registry outcomes with meta-analysis of RCTs which use VARC and VARC-2 definitions [41], as well as the meta-analysis of studies based on VARC definitions [40]. The authors also provide the influence factors description through comparison of single registry for each complication. In the last part, the author will summarize some aspects needed to be updated from VARC-2 definitions.

4.1 Summary of proportion use VARC-2 overall TAVI registries
During the search period, there are 44 registries in total potentially identified. 50% of them followed the VARC-2 definitions, and 13 used VARC definitions, additionally 10 registries did not follow both VARC definitions. Comparing the clinical outcome reporting system between the registries who followed the VARC definitions and who did not, the author clearly found that the one followed VARC definition have more structured reporting system. To be noticed, the reporting system is not the factor to influence clinical outcome. The biggest advantage of uniform and structured reporting system is to help comparing clinical outcome among different registries or study groups. The registries that did not follow VARC definition report clinical outcome mostly based on patients’ medical records; as a result, the clinical outcome in these registries can be only compared with their own patients’ baseline characteristics. It is impossible to compare clinical outcome with other registries. Another notice from the registries not following VARC definitions is that these registries do not separate cardiovascular mortality from all-cause mortality, which may be misleading, resulting in disproportionate reporting of mortal events unrelated to either the treatment device or the procedure [10,11].
Complications are defined uniformly in all studies using VARC definitions, which make clinical outcome comparison available. Available comparison gives the researchers a chance to do systematic review as well as meta-analysis. This point can be proved by the number of systematic review and meta-analysis in the field of TAVI. The authors make a brief search in PubMed (Medline) database for the number of systematic review (SR) and meta-analysis (MA) in the field of TAVI. The result proved our hypothesis. We found one SR in 2010 and 2011, respectively; one SR and two MA in 2012; four MA were conducted in 2013, which started to mention VARC definitions in the result part; there were eight SR and MA published in 2014; the number of published SR and MA in 2015 and 2016 is 16, 10, respectively. The trend of formulating a SR or MA is from focusing one complication to all complications after the introduction of VARC definitions; in addition, the study design is changing from based on medical records, to analyze the result according to VARC definitions, to just reviewing the studies reporting clinical outcome based on VARC definitions.

4.2 Single complication reporting needs to be noticed

The result part illustrates how TAVI registries report clinical outcome according to VARC-2 definition for mortality and each complication. In the following text the author will discuss what should be notified when report mortality and major complications according to VARC-2 definition. In addition, although the result summarizing from each single studies is not the priority focus of our review, the results comparison can show if the reporting system influences the clinical outcome, and which aspects can influence single complication. In this part, the author will compare the result gotten from our review to the meta-analysis based on VARC definitions and based on RCTs, then to highlight the general accepted influence factors for each complication.

4.2.1 Mortality. The reporting of CV mortality at 30 days and immediate procedural mortality is vital to the cumulative clinical experience. Therefore, VARC-2 recommends the collection of immediate procedural mortality data to capture intra-procedural events that result in immediate or consequent death within 72 hours post-procedure [11]. However, there is no registry to report immediate procedural mortality data of all included studies, and only 14 registries reported CV mortality at 30 days. It is already stated in the VARC definitions that it is essential to report CV mortality to reduce disproportionate reporting of mortal events unrelated to either the treatment or to the procedure [10].

Because there may be either under-reporting of early device failure or unknown status at early report times, VARC definitions are suggesting all-cause mortality at 1 year as a primary endpoint for TAVI clinical trials [10]. In our review, only 10 registries reported 1-year all-cause mortality. To increase patients’ safety and avoid under-reporting of early device failures, registries should focus on long-term follow up, especially 1-year clinical outcomes. Outcome reporting should be established for both at 30-day as well as at 1-year. If the mortality rates are significantly different when comparing 30-day and 1-year data, the registry should list and clarify the cause of death.

In our review the 30-day all-cause mortality ranged from 0 to 12.7% [19,25]. Eight studies from our review reported a rate of 30-day all-cause mortality about 6.0% [41]. The 30-day all-cause mortality from a pooled analysis of studies based on VARC is 7.8% [40], which is comparable with the result from our study; the result from 5 RCTs is 3.7% [41], which is better than the result from our study, main reason is that the patients selection from for RCTs is lower risk and have a better prognosis. The patient selection is one of the influence factors of mortality, especially cardiovascular mortality. In addition, De Brito et al. demonstrated that the training program and supervision provided to centers can reduce the mortality rate [24]. It could be confirmed that the rate of mortality was impacted by the program volume, with the risk of
death being 2.5 times greater in low volume centers [27]. Low hospital volume status was associated with significantly greater odds of death, bleeding, and MI, which was demonstrated by a study from the US national representative database [42].

4.2.2 Myocardial infarction (MI). It is recommended that MI reporting differentiate between periprocedural MI (<72h) and spontaneous MI (>72h) [11]. VARC-2 recommends the systematic collection of biomarkers of myocardial injury prior to the procedure, within 12–24 hours after the procedure, at 24 hours thereafter, at 72 hours or at discharge [11]. However, in our review, we identified only 11 registries who reported periprocedural MI. Most of registries presented MI rates ranging from 0.5% to 2% in present review. A similar result can be also found in Genereux et al. based on VARC definitions, of 1.1% [40]. The result from 5 RCTs has the same MI rate, which is 1.1% [41]. The SOURCE ANZ Registry reported a higher MI rate of 3.9%, the TA-TAVI group with 62 patients in this registry achieved an even higher MI rate with 6.45% [21]. Similar results could be found in the TAVI-Karlsruhe Registry, where periprocedural MI occurred in 2.7% of the 413 patients who underwent TA route [43]. It might be argued that this high number of MI is due to TA routes. However, this is not reflected by a meta-analysis presented by Panchal et al., that the incidence of MI was not statistically significant between the TF and TA TAVI groups [44]. Besides the access route, sex difference might be an influence factor of having post-MI, the WIN-TAVI Real-World Registry [23] with a group of female patients had very low MI rate (0.2). In addition, the development of device and TAVI procedure also help to reduce the rate of MI, which showed in the Sapien XT group in the Swiss TAVI Registry [17], which had a rate of post-MI of 0.

4.2.3 Stroke. According to VARC-2 definitions, the all-stroke rate includes TIA, disabling stroke and non-disabling stroke [11]. 19 registries reported all-stroke rate, which ranged from 0.6% to 7% in the present review [25,33]. The all-stroke rate reported by Muralidharan et al. was 3.07% in 29,043 patients [45]. The rate of all neurological events estimated by Genereux et al. was 5.7% [40]. The result from 5 RCTs is 5.3%, which has no big difference with the result from registries [41]. Siemieniuk et al. demonstrated that TA-group patients had a higher incidence of stroke occurrence, with 6.5% higher than that of TF-group patients [46]. However, a single center study from our review displayed different results, which showed a stroke incidence within the TF group is higher than that within the TA group (2.3% vs. 1.7%) [43]. In addition, older patients may have a higher risk of stroke than younger patients. If patients have better baseline characteristics, they will have a better outcome. For example, the logistic Euro-Score for Nassy database is 16.1±13.1, just one person has stroke afterwards [25]. Perioperative stroke is closely related to mortality rate. Muralidharan et al. reported 30-day stroke-related mortality rate of 12.27%, which is 4 times higher for patients with perioperative stroke in comparison to patients without perioperative stroke (28.22% vs. 6.40%).

4.2.4 Bleeding. Bleeding complications should be reported in three categories: life-threatening or disabling bleeding, major bleeding and minor bleeding [11]. The reporting situation of bleeding rate is satisfactory in our review. The authors can identified both life-threatening bleeding and major bleeding from 18 registries. The overall bleeding rate ranged from 4.6% in the University Hospital Zurich TAVI Registry [29] to 43.3% in the PRAGMATIC Multicenter Study [15]. In the PRAGMATIC Study, 19.1% of patients experienced major bleeding [15]. Genereux et al. reported major bleeding rate of 22.3%, and life-threatening bleeding rate of 15.6% [40]. In addition, 5 RCTs reported a major bleeding rate of 16.4% [41]. Siemieniuk et al. reported that bleeding was reduced with use of both TF-TAVI (25.2%) and TA-TAVI (19.4%) as compared with SAVR [46]. This result is in line with the result of a single study from our review, which showed a similar result from both TF and TA groups (28.6% vs. 28.8%) [43].

4.2.5 Acute kidney injury (AKI). There are 3 stages of AKI based on VARC-2 definitions: stages 1, 2, and 3. In our review, the rate of AKI stage 2 and AKI stage 3 can be only identified
from 8 registries. Most registries have a rate of AKI stage 2 to 3 with 2.0% to 3.0% in our review. The ITER Registry had a higher rate of 8.14% of AKI stage 2 to 3, also with a higher rate of life-threatening and major bleeding of 20.53% [20]. A similar result can be found in the PRAGMATIC Multicenter Study, which reports a rate of life-threatening combined with major bleeding, AKI stages 2 to 3, 32.20% and 9.22% respectively [15]. The interaction between bleeding and AKI in TAVI patients remains unclear, and should be investigated in future studies. The pooled estimate rate of AKI stages 2 to 3 by Genereux et al. from 1,275 patients was 7.5% [40]. The rate of AKI from the meta-analysis of 5 RCTs is 2.5% [41]. Siemieniuk et al. showed a higher risk of TA-TAVI than TF-TAVI when receiving AKI post procedure [46]. This is also demonstrated by Schymik et al., who report that the TF group had a lower rate of AKI than TA group (19.9% vs. 35.1%) [43].

4.2.6 Vascular complications. Vascular complications can be categorized into two types: major vascular complication and minor vascular complication. All of the identified registries have reported vascular complication rates in our review. Most studies in our review reported vascular complications ranging from 3.7% to 9.8%. Major vascular complications occurred in 11.9% of patients as reported by Genereux et al. [40]. The vascular complications rate from RCTs is 7.9%, which is better than the result from registries [41]. Patients were more likely to experience vascular complications following TAVI compared to SAVR [41,46]. The TF-TAVI group of 587 patients in the TAVI-Karlsruhe Registry had a higher vascular complication rate with 17.55% [28], the result from their TA group was 2.42% [28]. It is generally accepted, that the TA approach has been associated with a lower rate of vascular complications than the TF route [47–49]. The author assumed that the influence factor of patients having vascular complications after TAVI have highly relevant to the access route, but not the baseline characteristics, like the logistic EuroScore for Nassy database is 16.1±13.1, there are still 15.2% patients in this registry have vascular complications afterwards [25].

4.2.7 New pacemaker implantation. VARC-2 proposes the systematic collection of data on the frequency of implant-related new permanent pacemaker implantation [11]. The reporting outcome can be identified from all the registries in our review. The overall new pacemaker implantation rate in our review is similar to the previous meta-analysis, where the rate of new pacemaker implantation was 13.9% [40]. The result is also similar to the result taken from RCTs, which is 14.4% [41]. New permanent pacemaker implantation was more common with TAVI than SAVR [41,46]. It is generally accepted that the self-expandable CoreValve has a higher rate of new pacemaker requirement than Edwards valve [40]. This can be reflected from our review, the rate from pure Edwards registries ranged from 3.8% to 17.0% [17,19], and 23.63% of patients needed a new pacemaker after TAVI in the pure CoreValve registry [22]. And it is showed in Nordic Lotus-TAVR registry [32] and DISCOVER Study [33], the new device has also a higher rate of new pacemaker requirement than Edwards valve.

4.2.8 Composite endpoint. VARC-2 definitions recommended composite endpoints for TAVI safety and effectiveness [10,11]. However, in our study, the reporting status from identified registries was disappointing. For example, 11 studies reported an early safety rate, but it ranged from 10% to 92.2%, only three registries reported a rate of clinical efficacy, and no registry report a rate for time-related valve safety. This lack of data could be because the registry groups misunderstand the calculation of composite endpoint, or that they do not have any data to report.

4.3 Some aspects needed to be updated from VARC-2 definitions
The reason why TAVI registries not following VARC definitions are mainly because that the time they collected data was before the introduction of the VARC definition. The other reason
is because the registry aimed to investigate some special complications after undergoing TAVI, one study performed by the GAMES database aimed to describe the characteristics of infective endocarditis after undergoing TAVI[50]; the multicenter German TAVI registry aimed to predict the relations between mortality and aortic regurgitation after TAVI [51]. This can be also reflected from the current systematic review and meta-analysis, which aimed to investigate special complications like endocarditis, cognitive functions, leak post-transcatheter as well as quality of life, did not require included studies designing based on VARC definitions. The registries not following VARC definition also indicate that medical procedure and experience are developing; a standard recommendation needs to be updated to fulfill the development of medical technology and clinical experience.

4.4 Study limitations
There are several limitations in this review. First of all, the authors were only able to review articles in English. Therefore, some important article could be missing. In addition, this review focused on major complications based on VARC-2 definitions. The authors did not analyze other complications, which could also influence the result.

5. Conclusion
VARC and VARC-2 definitions are more and more widely used in clinical studies as well as in registry studies. However, since their introduction in 2011, VARC definitions are still not systematically reported in TAVI studies. These endpoint definitions warrant a concise and systemic analysis of outcome measures in high-risk patient populations. These standardized endpoint definitions make study result comparisons feasible, providing better insights by differentiating products and approaches, and thus increasing transparency for patients.

For regulatory bodies, standardized reporting based on VARC-2 can support post-market surveillance of already approved TAVI products to monitor safety and to react to adverse events timely. For HTA agencies VARC-2 definitions allow pooled analyses of various studies, and thus provide sufficient evidence on cost and effectiveness of different types of products and different access routes. Taking VARC-2 definitions into account, payers can choose the most appropriate procedure for different patient groups, making TAVI more effective and less costly.

Supporting information
S1 Table. PRISMA checklist. This manuscript is a systematic review in line with PRISMA checklist.

(DOC)

Acknowledgments
The research is supported by the German Federal Ministry of Education and Research (BMBF), as part of the National Leading-Edge Cluster Medical Technologies 'Medical Valley EMN'.

The present work was performed in (partial) fulfillment of the requirements for obtaining the degree “Dr. rer. biol. hum.” at the Medical Faculty of Friedrich-Alexander University of Erlangen-Nürnberg.

Author Contributions
Conceptualization: PLKR.
Formal analysis: SZ.
Funding acquisition: PLKR.
Investigation: PLKR SZ.
Methodology: PLKR SZ.
Project administration: PLKR.
Resources: SZ.
Supervision: PLKR.
Validation: PLKR.
Visualization: SZ.
Writing – original draft: SZ.
Writing – review & editing: PLKR.

References

1. Manning WJ (2013) Asymptomatic aortic stenosis in the elderly: a clinical review. Jama 310: 1490–1497. https://doi.org/10.1001/jama.2013.279194 PMID: 24104373
2. Czarny MJ, Resar JR (2014) Diagnosis and management of valvular aortic stenosis. Clin Med Insights Cardiol 8: 15–24.
3. Alonso Gomez AM, Gomez de Diego JJ, Barba J, Baron G, Borras X, et al. (2013) Comments on the ESC guidelines on the management of valvular heart disease (version 2012). A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology. Rev Esp Cardiol (Engl Ed) 66: 85–89.
4. Iung B, Baron G, Butchart EG, Delahaye F, Gohlie-Barwolf C, et al. (2003) A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 24: 1231–1243. PMID: 12831818
5. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, et al. (2011) Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364: 2187–2198. https://doi.org/10.1056/NEJMo1103510 PMID: 21639811
6. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, et al. (2014) 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63: 2438–2488. https://doi.org/10.1016/j.jacc.2014.02.537 PMID: 24603192
7. Cribier A, Etchanchioff H, Bash A, Borenstein N, Tron C, et al. (2002) Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 106: 3006–3008. PMID: 12473543
8. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, et al. (2010) Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363: 1597–1607. https://doi.org/10.1056/NEJMoa1008232 PMID: 20961243
9. Webb JG, Pasupati S, Humphries K, Thompson C, Altweig L, et al. (2007) Percutaneous transarterial aortic valve replacement in selected high-risk patients with aortic stenosis. Circulation 116: 755–763. https://doi.org/10.1161/CIRCULATIONAHA.107.698258 PMID: 1764579
10. Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, et al. (2011) Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol 57: 253–269. https://doi.org/10.1016/j.jacc.2010.12.005 PMID: 21216553
11. Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, et al. (2013) Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg 145: 6–23. https://doi.org/10.1016/j.jtcvs.2012.09.002 PMID: 23084102
12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj 339: b2700. https://doi.org/10.1136/bmj.b2700 PMID: 19622552
13. Margulis AV, Pladevall M, Riera-Guardia N, Varas-Lorenzo C, Hazell L, et al. (2014) Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol 6: 359–368. https://doi.org/10.2147/CLEP.S6677 PMID: 25336990

14. Tarantini G, Gasparetto V, Napodano M, Frigo AC, Fraccaro C, et al. (2013) Transcatheter aortic valve implantation and bleeding: Focus on Valve Academic Research Consortium-2 classification. International Journal of Cardiology 168: 5001–5003. https://doi.org/10.1016/j.ijcard.2013.07.123 PMID: 23931971

15. Chieffo A, Van Mieghem NM, Tchetche D, Dumontel N, Giustino G, et al. (2015) Impact of mixed aortic valve stenosis on VARC-2 outcomes and postprocedural aortic regurgitation in patients undergoing transcatheter aortic valve implantation: Results from the international multicentric study PRAGMATIC (Pooled Rotterdam-Milan-Toulouse in Collaboration). Catheterization and Cardiovascular Interventions 86: 875–885. https://doi.org/10.1002/ccd.25975 PMID: 26032764

16. Borz B, Durand E, Godin M, Torn C, Canville A, et al. (2014) Does residual aortic regurgitation after transcatheter aortic valve implantation increase mortality in all patients? the importance of baseline natriuretic peptides. International Journal of Cardiology 173: 436–440. https://doi.org/10.1016/j.ijcard.2014.03.011 PMID: 24679693

17. Binder RK, Stortecky S, Heg D, Tueller D, Jeger R, et al. (2015) Procedural Results and Clinical Outcomes of Transcatheter Aortic Valve Implantation in Switzerland: An Observational Cohort Study of Sapien 3 Versus Sapien XT Transcatheter Heart Valves. Circulation: Cardiovascular Interventions 8.

18. Kodali S, Thourani VH, White J, Mliaisirie SC, Lim S, et al. (2016) Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. European Heart Journal.

19. Salinas P, Moreno R, Calvo L, Sanchez-Recale S, Jimenez-Valero S, et al. (2016) Long-term Follow-up After Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis. Rev Esp Cardiol (Engl Ed) 69: 37–44.

20. Salizzoni S, D’Onofrio A, Agrifoglio M, Colombo A, Chieffo A, et al. (2016) Early and mid-term outcomes of 1904 patients undergoing transcatheter balloon-expandable valve implantation in Italy: results from the Italian Transcatheter Balloon-Expandable Valve Implantation Registry (ITER). Eur J Cardiothorac Surg.

21. Walters DL, Sinhal A, Baron D, Pasupati S, Thambar S, et al. (2014) Initial experience with the balloon expandable Edwards-SAPIEN Transcatheter Heart Valve in Australia and New Zealand: The SOURCE ANZ registry: Outcomes at 30 days and one year. International Journal of Cardiology 170: 406–412. https://doi.org/10.1016/j.ijcard.2013.11.027 PMID: 24300083

22. Petronio AS, Giannini C, De Carlo M, Bedogni F, Colomba A, et al. (2016) Anaesthetic management of transcatheter aortic valve implantation: results from the Italian CoreValve registry. EuroIntervention 12: 381–388. https://doi.org/10.4244/EIJY15M03_05 PMID: 25772903

23. Chieffo A, Petronio AS, Mehilli J, Chandrasekar J, Sartori S, et al. (2016) Acute and 30-Day Outcomes in Women After TAVR: Results From the WIN-TAVI (Women’s INternational Transcatheter Aortic Valve Implantation) Real-World Registry. JACC Cardiovasc Interv 9: 1589–1600. https://doi.org/10.1016/j.jcin.2016.05.015 PMID: 27491609

24. De Brito FS, Carvalho LA, Sarmento-Leite R, Mangione JA, Lemos P, et al. (2016) Outcomes and predictors of mortality after transcatheter aortic valve implantation: Results of the Brazilian registry. Catheterization and Cardiovascular Interventions 85: E153–E162.

25. Inohara T, Hayashida K, Watanabe Y, Yamamoto M, Takagi K, et al. (2016) Streamlining the learning process for TAVI: Insight from a comparative analysis of the OCEAN-TAVI and the massy registries. Catheter Cardiovasc Interv 87: 963–970. https://doi.org/10.1002/ccd.26266 PMID: 26489980

26. Martinez GJ, Seco M, Jaijee SK, Adams MR, Cartwright BL, et al. (2014) Introduction of an interdisciplinary heart team-based transcatheter aortic valve implantation programme: Short and mid-term outcomes. Internal Medicine Journal 44: 876–883. https://doi.org/10.1111/imj.12514 PMID: 24965193

27. Ribeiro HB, Nombela-Franco L, Muñoz-Garcia AJ, Lemos PA, Amat-Santos I, et al. (2015) Predictors and Impact of Myocardial Injury after Transcatheter Aortic Valve Replacement A Multicenter Registry. Journal of the American College of Cardiology 66: 2075–2088. https://doi.org/10.1016/j.jacc.2015.08.881 PMID: 26541917

28. Schymik G, Würth A, Bramlage P, Herbinger T, Heimeshoff M, et al. (2015) Long-term results of transapical versus transfemoral TAVI in a real world population of 1000 patients with severe symptomatic aortic stenosis. Circulation: Cardiovascular Interventions 8.

29. Tasnady H Outcomes after transcatheter aortic valve implantation: a single centre registry of 350 consecutive cases.
30. Van Mieghem NM, Dumonteil N, Chieffo A, Roux Y, Van Der Boon RMA, et al. (2016) Current decision making and short-term outcome in patients with degenerative aortic stenosis: The pooled-Rotterdam-Milano-Toulouse in collaboration aortic stenosis survey. Eurointervention 11: e1305–e1313. https://doi.org/10.4244/EUIV11I10A253 PMID: 26865449

31. Yoon SH, Ahn JM, Hayashida K, Watanabe Y, Shirai S, et al. (2016) Clinical Outcomes Following Transcatheter Aortic Valve Replacement in Asian Population. JACC: Cardiovascular Interventions 9: 926–933. https://doi.org/10.1016/j.jcin.2016.01.047 PMID: 27151607

32. De Backer O, Gotberg M, Ihlberg L, Packer E, Savontaus M, et al. (2016) Efficacy and safety of the Lotus Valve System for treatment of patients with severe aortic valve stenosis and intermediate surgical risk: Results from the Nordic Lotus-TAVR registry. Int J Cardiol 219: 92–97. https://doi.org/10.1016/j.ijcard.2016.05.072 PMID: 27288972

33. Lefèvre T, Colombo A, Tchétchê D, Latib A, Klugmann S, et al. (2016) Prospective Multicenter Evaluation of the Direct Flow Medical Transcatheter Aortic Valve System 12-Month Outcomes of the Evaluation of the Direct Flow Medical Percutaneous Aortic Valve 18F System for the Treatment of Patients with Severe Aortic Stenosis (DISCOVER) Study. JACC: Cardiovascular Interventions 9: 68–75. https://doi.org/10.1016/j.jcin.2015.09.027 PMID: 26762913

34. Walther T, Kemptt J (2012) Transapical vs. transfemoral aortic valve implantation: Which approach for which patient, from a surgeon's standpoint. Annals of Cardiothoracic Surgery 1: 216–219. https://doi.org/10.3978/j.issn.2225-319X.2012.07.10 PMID: 23977497

35. Landes U, Barshesheet A, Finkelstein A, Guetta V, Assali A, et al. (2016) Temporal trends in transcatheter aortic valve implantation, 2008–2014: patient characteristics, procedural issues, and clinical outcome. Clin Cardiol.

36. Reinöhl J, Kaier K, Reinecke H, Schmoor C, Frankenstein L, et al. (2015) Effect of Availability of Transcatheter Aortic-Valve Replacement on Clinical Practice. New England Journal of Medicine 373: 2438–2447. https://doi.org/10.1056/NEJMoa1500893 PMID: 26672846

37. de Brito Júnior FS, Siqueira D, Sarmento-Leite R, Carvalho LA, Neto PAL, et al. (2011) Rationale and design of the Brazilian Transcatheter Aortic Valve Implantation Registry. Revista Brasileira de Cardiologia Invasiva 19.

38. Mylotte D, Osnabrugge RL, Windcker S, Lefèvre T, de Jaegere P, et al. (2013) Transcatheter aortic valve replacement in Europe: adoption trends and factors influencing device utilization. J Am Coll Cardiol 62: 210–219. https://doi.org/10.1016/j.jacc.2013.03.074 PMID: 23684675

39. IQTIG (2015) Qualitätsreport 2015.

40. Geneurex P, Head SJ, Van Mieghem NM, Kodali S, Kirtane AJ, et al. (2012) Clinical outcomes after transcatheter aortic valve replacement using valve academic research consortium definitions: a weighted meta-analysis of 3,519 patients from 16 studies. J Am Coll Cardiol 59: 2317–2326. https://doi.org/10.1016/j.jacc.2012.02.022 PMID: 22503058

41. Indraratna P, Tian DH, Yan TD, Doyle MP, Cao C (2016) Transcatheter aortic valve implantation versus surgical aortic valve replacement: A meta-analysis of randomized controlled trials. Int J Cardiol 224: 382–387. https://doi.org/10.1016/j.ijcard.2016.09.018 PMID: 27673695

42. Kim LK, Minutello RM, Feldman DN, Swaminathan RV, Bergman G, et al. (2015) Association Between Transcatheter Aortic Valve Implantation Volume and Outcomes in the United States. Am J Cardiol 116: 1910–1915. https://doi.org/10.1016/j.amjcard.2015.09.046 PMID: 26508710

43. Schymik G, Heimeshoff M, Bramlage P, Herbinger T, Würth A, et al. (2015) A comparison of transcatheter aortic valve implantation and surgical aortic valve replacement in 1,141 patients with severe symptomatic aortic stenosis and less than high risk. Catheterization and Cardiovascular Interventions 86: 738–744. https://doi.org/10.1002/ccd.25866 PMID: 25641398

44. Panchal HB, Ladia V, Amin P, Patel P, Veeranki SP, et al. (2014) A meta-analysis of mortality and major adverse cardiovascular and cerebrovascular events in patients undergoing transfemoral versus transapical transcatheter aortic valve implantation using edwards valve for severe aortic stenosis. Am J Cardiol 114: 1882–1890. https://doi.org/10.1016/j.amjcard.2014.09.029 PMID: 25438917

45. Muralidharan A, Thiagarajan K, Van Ham R, Gleason TG, Mulukutta S, et al. (2016) Meta-Analysis of Perioperative Stroke and Mortality in Transcatheter Aortic Valve Implantation. Am J Cardiol 118: 1031–1045. https://doi.org/10.1016/j.amjcard.2016.07.011 PMID: 27634034

46. Siemieniuk RA, Agoritsas T, Manja V, Devji T, Chang Y, et al. (2016) Transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at low and intermediate risk: systematic review and meta-analysis. BMJ 354: i5130. https://doi.org/10.1136/bmj.i5130 PMID: 27683246

47. Thomas M, Schymik G, Walther T, Himbert D, Lefèvre T, et al. (2010) Thirty-Day Results of the SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry. Circulation 122: 62. https://doi.org/10.1161/CIRCULATIONAHA.109.907402 PMID: 20566953

38. Reinoehl J, Kaier K, Reinecke H, Schmoor C, Frankenstein L, et al. (2015) Effect of Availability of Transcatheter Aortic-Valve Replacement on Clinical Practice. New England Journal of Medicine 373: 2438–2447. https://doi.org/10.1056/NEJMoa1500893 PMID: 26672846
48. Lefèvre T, Kappetein AP, Wolner E, Nataf P, Thomas M, et al. (2011) One year follow-up of the multi-centre European PARTNER transcatheter heart valve study. European Heart Journal 32: 148–157. https://doi.org/10.1093/eurheartj/ehq427 PMID: 21075775

49. Walther T, Kasimir MT, Doss M, Schuler G, Simon P, et al. (2011) One-year interim follow-up results of the TRAVERCE trial: the initial feasibility study for trans-apical aortic-valve implantation. Eur J Cardiothorac Surg 39: 532–537. https://doi.org/10.1016/j.ejcts.2010.06.002 PMID: 20637648

50. Martinez-Selles M, Bouza E, Diez-Villanueva P, Valerio M, Farinas MC, et al. (2016) Incidence and clinical impact of infective endocarditis after transcatheter aortic valve implantation. EuroIntervention 11: 1180–1187. https://doi.org/10.4244/EIJY15M02_05 PMID: 25671426

51. Abdel-Wahab M, Zahn R, Gerckens U, Linke A, Sievert H, et al. (2014) Predictors of 1-year mortality in patients with aortic regurgitation after transcatheter aortic valve implantation: an analysis from the multi-centre German TAVI registry. Heart 100: 1250–1256. https://doi.org/10.1136/heartjnl-2013-305385 PMID: 24895354